Virtual Library
Start Your Search
J.M. Cabrera Romero
Author of
-
+
P3.03 - Poster Session with Presenters Present (ID 473)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Mesothelioma/Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
- Presentations: 1
- Moderators:
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.03-056 - Retrospective Study Comparing Two Frontline Chemotherapy Schemes in Unresectable Malignant Mesothelioma (ID 5724)
14:30 - 14:30 | Author(s): J.M. Cabrera Romero
- Abstract
Background:
Standard treatment for mesothelioma is platinum-based combination chemotherapy. Selected patients can benefit from surgical procedures and / or radiotherapy. We retrospectively reviewed the results of different platinum doublets administered in clinical practice in our centre.
Methods:
This is a single-centre study of 64 patients with mesothelioma treated with first-line palliative chemotherapy between September 1999 and December 2015. Patients were divided into 2 groups according to the treatment received: (A) 55 patients who received platinum + pemetrexed and (B) 9 patients treated with platinum + gemcitabine. The characteristics of the groups are compared and the results obtained presented.
Results:
Group A characteristics: 75.4% male, mean age 66.7 years. Origin: 91.2% pleural and peritoneal 5.3%. Histology: epithelioid 61.1%, 5.6% biphasic and 33% unknown. Clinical staging III and IV (50.9%) I and II (24.6%). They had PS0 = 31.6%, PS1= 57.9%, PS2 = 5.3%. Group 'B': 77.8% male, mean age 69.9 years. Origin: pleural 77.8% and 22.2% peritoneal. Epithelioid histology 44.4%, 22.2% sarcomatoid and 22.2% unknown. They had PS0 =11.1%, PS1 = 55.6%, PS2= 22.2%, PS3 = 11.1%. There were no significant differences between groups in either prognostic factors or in the indication of palliative pleurodesis. Progression-free survival (A) was 6.7 vs. (B) 2.53 months (p = 0.013). Overall survival (A) was 19.1 months vs. (B) 7.7 months (p = 0.046). The response rate was (A) 50% and (B) 11% (p = 0.19). They received second line: (A) 52.6% vs. (B) 1p (11.1%). G3-4 toxicities: (A) neutropaenia and asthenia (14.1%), anemia (7%), diarrhoea (3.5%), thrombocytopenia, nausea / vomiting, neuropathy, vascular, hearing and dysgeusia (1.8%). In (B) 2p anaemia (22.2%), diarrhoea 1p (11.1%). Median number of cycles (A) 6 vs. (B) 3 (p = 0.084). No significant differences in the number of delays and dose reductions between treatments were observed.
Conclusion:
A significant increase in PFS and OS was achieved with the combination of cisplatin and pemetrexed in our series. The toxicity profile is the expected one with a clinical benefit with cisplatin compared to gemcitabine.
